HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The efficacy of unoprostone isopropyl as an adjunct to topical beta-blocker in patients with open angle glaucoma: a-6-month study.

AbstractOBJECTIVES:
To assess the efficacy and safety of unoprostone isopropyl as an adjunctive treatment to topical beta-blocker in patients with primary open angle glaucoma (POAG).
STUDY DESIGN:
This was a prospective, open-label clinical study.
MATERIAL AND METHOD:
A total of 44 eyes of 22 eligible patients whose intraocular pressure (IOP) was inadequately controlled by topical beta-blocker were enrolled. Inclusion criteria consisted of patients with primary open angle glaucoma who either had IOP measurements > or = 22 mmHg while on topical beta-blocker monotherapy or had IOP measurements > or = 18 mmHg while on dual therapy (topical beta-blocker and a second drug of a different class which was to be discontinued prior to the study to allow washing out of its effects).
INTERVENTION:
Baseline IOP, pupil size, blood pressure and pulse rate were initially measured; the patients were then examined at 2nd, 4th, 8th, 12th, 18th and 24th weeks of following commencement of topical unoprostone isopropyl therapy (given twice daily).
MAIN OUTCOME MEASURES:
IOP pupil size, blood pressure and pulse rate were measured and were compared to baseline values.
RESULTS:
In 44 eyes of 22 eligible patients, unoprostone isopropyl resulted in a statistically significant IOP reduction of 24.6% (p < 0.02). The mean systolic blood pressure decreased from 132.79 +/- 22.11 mmHg (range 100-180 mmHg) at baseline to 125.77 +/- 18.40 mmHg (range 80-160 mmHg) at 24th week after unoprostone isopropyl administration. This reduction was statistically significant (p = 0.002) but was unlikely to have clinical importance. Both mean diastolic blood pressure (p = 0.344), pulse rate (p = 0.306), and pupil diameter (p = 0.107) were not significantly affected.
CONCLUSION:
Topical unoprostone isopropyl beneficially provides additive IOP lowering effect to topical beta-blocker in patients with primary open angle glaucoma. No serious systemic side effects were found in the present study.
AuthorsYupin Leelachaikul, Ataya Euswas
JournalJournal of the Medical Association of Thailand = Chotmaihet thangphaet (J Med Assoc Thai) Vol. 88 Suppl 9 Pg. S100-4 (Nov 2005) ISSN: 0125-2208 [Print] Thailand
PMID16681060 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Adrenergic beta-Antagonists
  • Ophthalmic Solutions
  • isopropyl unoprostone
  • Dinoprost
Topics
  • Administration, Topical
  • Adrenergic beta-Antagonists (administration & dosage)
  • Adult
  • Aged
  • Aged, 80 and over
  • Dinoprost (administration & dosage, analogs & derivatives)
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Glaucoma, Open-Angle (diagnosis, drug therapy)
  • Humans
  • Intraocular Pressure
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Prospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Single-Blind Method
  • Tonometry, Ocular
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: